Canaccord lowered the firm’s price target on DexCom (DXCM) to $82 from $100 and keeps a Buy rating on the shares. The firm atteended its Investor Day where management outlined its base case financial targets that they believe should be easily attainable given the company’s timeline of catalysts, namely product launches and the improving global CGM coverage landscape.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: